Developer docs
API playgroundTry for free, no card

Search company profiles

Biossil

Full company profile

uuid0006vh3

Namestring
Biossil
Legal namestring
Biossil
Websiteurl
biossil.co
Company typeenum
Private
Founded yearint
2023
Descriptiontext

Biossil is a Toronto-based AI-native biopharma company founded in 2023 that operates a proprietary drug rescue platform designed to identify promising molecules from failed clinical trials and reposition them for new therapeutic indications. Rather than conducting de novo drug discovery, the company acquires or licenses failed or deprioritized candidates and applies generative and predictive machine learning — including a referenced GEMOD (Gene Embedding to Mechanism of Action Distance) analytical framework — to assess their potential in alternative disease contexts. The pipeline spans late-stage clinical programs in sickle cell disease, idiopathic pulmonary fibrosis, glioblastoma, breast cancer, and Alzheimer's disease, with additional trials launching in hereditary xerocytosis, cisplatin-associated nephrotoxicity, basal cell carcinoma/squamous cell carcinoma, MPS VI, GI-acute radiation syndrome, and premature ovarian failure, and future programs in portal hypertension, radiation dermatitis, necrotizing soft tissue infection, vaso-occlusive crises, and diabetic cardiomyopathy.

The portfolio has been assembled through a combination of in-licensing and asset acquisitions: in October 2025 the company secured exclusive global rights to Medivir's topical HDAC inhibitor remetinostat (Phase 2, up to USD 60M in potential milestones and royalties) and acquired Galera Therapeutics' dismutase mimetics portfolio (avasopasem and rucosopasem, up to $105-108.5M in total deal value), assuming all development and commercialization obligations. The company exited stealth in April 2026 with approximately $70 million USD in equity funding from OpenAI, Founders Fund, 137 Ventures, DRI Healthcare Trust, Golden Ventures, Modern Capital, Panache Ventures, Quiet Capital, and Staircase Ventures, and operates from headquarters in Toronto with a secondary office in Boston, employing roughly 30 staff led by CEO Alexander I. Mosa (MD PhD) and Co-founder Anthony Mouchantaf (JD MBA).

Biossil's business model is licensing- and milestone-based: the company generates future revenue through drug development outcomes, partnering deals, milestone payments, and ultimately royalties upon successful development and commercialization of its repositioned candidates. As a clinical-stage company with no approved products, it currently has no commercial product revenue; distribution post-approval is anticipated to flow through traditional pharmaceutical channels including wholesalers, pharmacies, hospitals, and specialty pharmacies. End users are patients with life-threatening and rare conditions across oncology, neurodegeneration, hematology, fibrotic disease, and rare genetic disorders.

Short descriptiontext

Biossil is a Toronto-based AI-native biopharma company that uses a proprietary machine learning platform to identify and reposition promising molecules from failed clinical trials, developing late-stage treatments for patients with life-threatening and rare diseases across oncology, hematology, and neurodegeneration.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersToronto, Canada
HQ citystring
Toronto
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI drug discovery, drug repositioning platform, clinical stage biopharma, failed trial molecules, rare disease therapeutics
Industry1 code
PRIMARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Pharmaceutical Drug Development
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Drug Development and Licensing
TypeLicensing Royalties
Description

Biossil acquires or licenses molecules from failed clinical trials and develops them through clinical trials, potentially earning milestone payments and royalties upon successful development and commercialization. Revenue is generated through drug development outcomes, partnering deals, and eventual product commercialization.

betakit.com
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Biossil is an AI-native biopharma company that operates a proprietary drug rescue platform to identify promising molecules from failed clinical trials. The company acquires or licenses these failed drug candidates and uses AI analysis to reposition them for new therapeutic indications, focusing on late-stage programs in life-threatening diseases with urgent unmet medical needs such as sickle cell disease, idiopathic pulmonary fibrosis, glioblastoma, breast cancer, and Alzheimer's disease.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Biossil is an AI-native biopharma company that operates a proprietary drug rescue platform to identify and develop promising molecules from failed clinical trials. Rather than starting drug discovery from scratch, the company acquires or licenses failed drugs and uses AI analysis to reposition them for new therapeutic indications. The company maintains multiple late-stage clinical programs across life-threatening diseases including sickle cell disease, idiopathic pulmonary fibrosis, glioblastoma, breast cancer, and Alzheimer's disease. Biossil has expanded its portfolio through strategic acquisitions (dismutase mimetics portfolio from Galera including avasopasem and rucosopasem) and licensing agreements (remetinostat from Medivir), with additional programs in hereditary xerocytosis, MPS VI, diabetic cardiomyopathy, and other rare diseases.

Product and service13 records
1AI Drug Rescue Platform
CategoryCore Platform
2Sickle Cell Disease Program
CategoryClinical Program
3Idiopathic Pulmonary Fibrosis Program
CategoryClinical Program
4Glioblastoma Program
CategoryClinical Program
5Breast Cancer Program
CategoryClinical Program
6Alzheimer's Disease Program
CategoryClinical Program
7Remetinostat
CategoryIn-Licensed Asset
8Avasopasem
CategoryAcquired Asset
9Rucosopasem
CategoryAcquired Asset
10Rivipansel
CategoryClinical Program
11Odiparcil
CategoryClinical Program
12Caficistat
CategoryClinical Program
13Reltecimod
CategoryClinical Program
Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2025-10-23
Description

Biossil received exclusive global rights from Medivir to develop and commercialize remetinostat, a topical HDAC inhibitor in phase 2 trials. Medivir could receive up to USD 60 million in milestone payments and royalties if the drug is approved.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2025-10-23
Description

Exclusive licensing agreement for remetinostat development rights, a topical HDAC inhibitor. Biossil assumes global development responsibilities with potential milestone and royalty payments to Medivir.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2025-10-22
Description

Biossil acquired Galera Therapeutics' dismutase mimetics portfolio including avasopasem and rucosopasem for up to $105 million. Biossil assumes development and commercialization obligations including royalties, with the assets in clinical trials for head and neck cancer and pancreatic cancer.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2025-10-22
Description

Asset Purchase Agreement for dismutase mimetics portfolio acquisition including all formulations and indications, with potential total value up to $108.5 million. Biossil assumed ongoing development and commercialization obligations.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Clinical-stage company developing repositioned therapeutics including drugs originally developed by larger pharmaceutical companies. Comparable in pursuing late-stage repositioning plays for unmet-need indications.

TypeDirect peer
Description

Clinical-stage AI-native biopharma combining high-throughput biology with machine learning to advance a multi-indication pipeline. Closely comparable to Biossil's AI-platform + late-stage clinical asset model.

TypeDirect peer
Description

AI-native drug discovery startup funded to apply frontier AI models to therapeutics development. Comparable as a recent, well-capitalized AI-biotech entrant pursuing a similar platform-plus-pipeline strategy.

TypeDirect peer
Description

Computational drug discovery platform with both internal pipeline and partnered programs. Comparable in using physics- and ML-based methods to accelerate small-molecule drug discovery.

TypeDirect peer
Description

AI-first biologics design company using generative models to create novel protein therapeutics. Comparable as a well-funded AI-native biopharma pursuing a platform-plus-pipeline model.

TypeDirect peer
Description

AI-driven precision medicine company developing small-molecule therapeutics using automated drug design. Comparable as an early AI-drug-discovery company that has progressed multiple candidates into the clinic.

TypeDirect peer
Description

AI drug discovery company applying machine learning to identify new drug targets and reposition existing assets. Comparable in using AI specifically for drug repositioning and indication selection across multiple programs.

TypeDirect peer
Description

AI-driven drug discovery company using machine learning on human data to develop therapeutics across multiple indications. Comparable in being an AI-native platform company translating computational methods into clinical assets.

TypeOthers
Description

Clinical-stage biotech whose dismutase mimetics portfolio was acquired by Biossil. Highly relevant counterparty: Biossil is essentially continuing Galera's oncology supportive-care pipeline (avasopasem, rucosopasem) in head & neck, pancreatic, and other cancers.

10Isomorphic Labs
TypeDirect peer
Description

Alphabet-owned AI drug discovery company spun out of DeepMind. Comparable as a high-profile AI-native biopharma applying foundation models to therapeutic discovery and development.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors12 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Biossil

Pharmaceutical Drug Developmentbiossil.co

Biossil is a Toronto-based AI-native biopharma company that uses a proprietary machine learning platform to identify and reposition promising molecules from failed clinical trials, developing late-stage treatments for patients with life-threatening and rare diseases across oncology, hematology, and neurodegeneration.

What Biossil does

Biossil is a Toronto-based AI-native biopharma company founded in 2023 that operates a proprietary drug rescue platform designed to identify promising molecules from failed clinical trials and reposition them for new therapeutic indications. Rather than conducting de novo drug discovery, the company acquires or licenses failed or deprioritized candidates and applies generative and predictive machine learning — including a referenced GEMOD (Gene Embedding to Mechanism of Action Distance) analytical framework — to assess their potential in alternative disease contexts. The pipeline spans late-stage clinical programs in sickle cell disease, idiopathic pulmonary fibrosis, glioblastoma, breast cancer, and Alzheimer's disease, with additional trials launching in hereditary xerocytosis, cisplatin-associated nephrotoxicity, basal cell carcinoma/squamous cell carcinoma, MPS VI, GI-acute radiation syndrome, and premature ovarian failure, and future programs in portal hypertension, radiation dermatitis, necrotizing soft tissue infection, vaso-occlusive crises, and diabetic cardiomyopathy.

The portfolio has been assembled through a combination of in-licensing and asset acquisitions: in October 2025 the company secured exclusive global rights to Medivir's topical HDAC inhibitor remetinostat (Phase 2, up to USD 60M in potential milestones and royalties) and acquired Galera Therapeutics' dismutase mimetics portfolio (avasopasem and rucosopasem, up to $105-108.5M in total deal value), assuming all development and commercialization obligations. The company exited stealth in April 2026 with approximately $70 million USD in equity funding from OpenAI, Founders Fund, 137 Ventures, DRI Healthcare Trust, Golden Ventures, Modern Capital, Panache Ventures, Quiet Capital, and Staircase Ventures, and operates from headquarters in Toronto with a secondary office in Boston, employing roughly 30 staff led by CEO Alexander I. Mosa (MD PhD) and Co-founder Anthony Mouchantaf (JD MBA).

Biossil's business model is licensing- and milestone-based: the company generates future revenue through drug development outcomes, partnering deals, milestone payments, and ultimately royalties upon successful development and commercialization of its repositioned candidates. As a clinical-stage company with no approved products, it currently has no commercial product revenue; distribution post-approval is anticipated to flow through traditional pharmaceutical channels including wholesalers, pharmacies, hospitals, and specialty pharmacies. End users are patients with life-threatening and rare conditions across oncology, neurodegeneration, hematology, fibrotic disease, and rare genetic disorders.

Biossil firmographics

Firmographics
Name
Biossil
Legal name
Biossil
Website
https://biossil.co
Company type
Private
Founded year
2023
Operating status
Operating
Headcount range
1–10 employees
Short description
Biossil is a Toronto-based AI-native biopharma company that uses a proprietary machine learning platform to identify and reposition promising molecules from failed clinical trials, developing late-stage treatments for patients with life-threatening and rare diseases across oncology, hematology, and neurodegeneration.
Ownership category
akta.pro rank

Biossil industry classification

Industry
Product category
Pharmaceutical Drug Development
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • AI drug discovery
  • Drug repositioning platform
  • Clinical stage biopharma
  • Failed trial molecules
  • Rare disease therapeutics

Where Biossil is headquartered

Location

Headquarters

HQ city
Toronto
HQ country
Canada
HQ region
North America

Offices2 records

Markets served

Biossil business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain

Revenue model

  1. Drug Development and Licensing: Biossil acquires or licenses molecules from failed clinical trials and develops them through clinical trials, potentially earning milestone payments and royalties upon successful development and commercialization. Revenue is generated through drug development outcomes, partnering deals, and eventual product commercialization.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Biossil product offering

Product offering

Core offering

Biossil is an AI-native biopharma company that operates a proprietary drug rescue platform to identify promising molecules from failed clinical trials. The company acquires or licenses these failed drug candidates and uses AI analysis to reposition them for new therapeutic indications, focusing on late-stage programs in life-threatening diseases with urgent unmet medical needs such as sickle cell disease, idiopathic pulmonary fibrosis, glioblastoma, breast cancer, and Alzheimer's disease.

Product overview

Biossil is an AI-native biopharma company that operates a proprietary drug rescue platform to identify and develop promising molecules from failed clinical trials. Rather than starting drug discovery from scratch, the company acquires or licenses failed drugs and uses AI analysis to reposition them for new therapeutic indications. The company maintains multiple late-stage clinical programs across life-threatening diseases including sickle cell disease, idiopathic pulmonary fibrosis, glioblastoma, breast cancer, and Alzheimer's disease. Biossil has expanded its portfolio through strategic acquisitions (dismutase mimetics portfolio from Galera including avasopasem and rucosopasem) and licensing agreements (remetinostat from Medivir), with additional programs in hereditary xerocytosis, MPS VI, diabetic cardiomyopathy, and other rare diseases.

Differentiator

Problem solved

Functional benefit

Products and services

  • AI Drug Rescue Platform
  • Sickle Cell Disease Program
  • Idiopathic Pulmonary Fibrosis Program
  • Glioblastoma Program
  • Breast Cancer Program
  • Alzheimer's Disease Program
  • Remetinostat
  • Avasopasem
  • Rucosopasem
  • Rivipansel
  • Odiparcil
  • Caficistat
  • Reltecimod

Companies that use Biossil

Customer profile

Segments1 record

Ideal customer profiles2 records

Biossil technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature1 record

Biossil partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core.

  • Medivir ABcoreOEM/ Whitelabel/ Licensing Partner · 23 October 2025Biossil received exclusive global rights from Medivir to develop and commercialize remetinostat, a topical HDAC inhibitor in phase 2 trials. Medivir could receive up to USD 60 million in milestone payments and royalties if the drug is approved.
  • Medivir ABcoreOEM/ Whitelabel/ Licensing Partner · 23 October 2025Exclusive licensing agreement for remetinostat development rights, a topical HDAC inhibitor. Biossil assumes global development responsibilities with potential milestone and royalty payments to Medivir.
  • Galera TherapeuticscoreOEM/ Whitelabel/ Licensing Partner · 22 October 2025Biossil acquired Galera Therapeutics' dismutase mimetics portfolio including avasopasem and rucosopasem for up to $105 million. Biossil assumes development and commercialization obligations including royalties, with the assets in clinical trials for head and neck cancer and pancreatic cancer.
  • Galera TherapeuticscoreOEM/ Whitelabel/ Licensing Partner · 22 October 2025Asset Purchase Agreement for dismutase mimetics portfolio acquisition including all formulations and indications, with potential total value up to $108.5 million. Biossil assumed ongoing development and commercialization obligations.

Scale indicators2 records

Recent moves5 records

Expansion highlights5 records

Biossil competitors and assessment

Company assessment

Emerging players

  • Biovie: Clinical-stage company developing repositioned therapeutics including drugs originally developed by larger pharmaceutical companies. Comparable in pursuing late-stage repositioning plays for unmet-need indications.

Direct peers

  • Recursion Pharmaceuticals: Clinical-stage AI-native biopharma combining high-throughput biology with machine learning to advance a multi-indication pipeline. Closely comparable to Biossil's AI-platform + late-stage clinical asset model.
  • Xaira Therapeutics: AI-native drug discovery startup funded to apply frontier AI models to therapeutics development. Comparable as a recent, well-capitalized AI-biotech entrant pursuing a similar platform-plus-pipeline strategy.
  • Schrödinger: Computational drug discovery platform with both internal pipeline and partnered programs. Comparable in using physics- and ML-based methods to accelerate small-molecule drug discovery.
  • Generate Biomedicines: AI-first biologics design company using generative models to create novel protein therapeutics. Comparable as a well-funded AI-native biopharma pursuing a platform-plus-pipeline model.
  • Exscientia: AI-driven precision medicine company developing small-molecule therapeutics using automated drug design. Comparable as an early AI-drug-discovery company that has progressed multiple candidates into the clinic.
  • BenevolentAI: AI drug discovery company applying machine learning to identify new drug targets and reposition existing assets. Comparable in using AI specifically for drug repositioning and indication selection across multiple programs.
  • Insitro: AI-driven drug discovery company using machine learning on human data to develop therapeutics across multiple indications. Comparable in being an AI-native platform company translating computational methods into clinical assets.
  • Isomorphic Labs: Alphabet-owned AI drug discovery company spun out of DeepMind. Comparable as a high-profile AI-native biopharma applying foundation models to therapeutic discovery and development.

Others

  • Galera Therapeutics: Clinical-stage biotech whose dismutase mimetics portfolio was acquired by Biossil. Highly relevant counterparty: Biossil is essentially continuing Galera's oncology supportive-care pipeline (avasopasem, rucosopasem) in head & neck, pancreatic, and other cancers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Biossil social profiles

Digital presence

Biossil financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Biossil leadership team

Management profile

Number of profiles

Profiles3 records

Biossil funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Biossil M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biossil

What does Biossil do?

Biossil is an AI-native biopharma company that operates a proprietary drug rescue platform to identify promising molecules from failed clinical trials. The company acquires or licenses these failed drug candidates and uses AI analysis to reposition them for new therapeutic indications, focusing on late-stage programs in life-threatening diseases with urgent unmet medical needs such as sickle cell disease, idiopathic pulmonary fibrosis, glioblastoma, breast cancer, and Alzheimer's disease.

Is Biossil a public or private company?

Biossil is a private company. It is classified as venture growth investor backed and is currently operating.

When was Biossil founded?

Biossil was founded in 2023. It employs 1 to 10 people.

Where is Biossil based?

Biossil is headquartered in Toronto, Canada, in the North America region.

How does Biossil make money?

One revenue line is on record: drug Development and Licensing.

Who are Biossil's main competitors?

Biovie is listed as an emerging player. Direct peers are Recursion Pharmaceuticals, Xaira Therapeutics, Schrödinger, Generate Biomedicines, Exscientia, BenevolentAI, Insitro and Isomorphic Labs. Galera Therapeutics is listed as an others.

Does Biossil have an API?

No public API is recorded for Biossil.

What industry is Biossil in?

Biossil's product category is Pharmaceutical Drug Development. Its primary akta.pro industry code is HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Quiver QuantitativeTheriva Reports $1.5 Million Third-Quarter Loss as VIRAGE2 Enrollment Advances | TOVX Stock NewsTheriva Biologics reported a $1.5 million net loss for Q3 2026, with cash and cash equivalents of $8.5 million. The company expects VIRAGE2 enrollment to complete in Q4 2026, with initial data by Q3 2027, and sold its SYN-004 portfolio to Biossil Labs for $350,000 upfront.YahooTheriva™ Biologics Announces Sale of SYN-004 (ribaxamase) and Related Antibiotic-Degrading Enzyme Portfolio to Biossil Labs Inc.Theriva Biologics sold its antibiotic-degrading enzyme portfolio, including SYN-004 (ribaxamase), to Biossil Labs. Theriva received a $350,000 upfront payment and is eligible for up to $91 million in regulatory and sales milestones plus royalties. Biossil assumed all development and commercialization costs.FierceBiotechOpenAI-funded Biossil snags Theriva's unwanted antibiotic degrader portfolio for up to $91MBiossil Labs acquired Theriva Biologics' deprioritized antibiotic-degrading enzyme portfolio for up to $91 million, including an upfront payment of $350,000 and potential milestones and royalties. The portfolio is led by SYN-004, which completed a phase 2b trial. Biossil will continue a phase 1b/2a study of SYN-004 in patients at risk of infection after hematopoietic cell transplant.The future of tradingAlligator Bioscience agrees to sell mitazalimab to BiossilAlligator Bioscience agreed to sell worldwide rights to mitazalimab to Biossil for $750,000 upfront, with contingent milestones totaling up to $108 million. The seller retains mid-single-digit royalties capped at $250 million, and closing is expected within 30 days.BetaKitBiossil hits unicorn status with new OpenAI-led financingBiossil, a Toronto-based biotech, raised $153 million USD at a $1 billion valuation in a round led by OpenAI. The funding will expand its clinical development capacity and acquire more drug candidates. The company plans to build AI-integrated infrastructure in the US and Canada.ThelogicOpenAI backs Biossil in US$153M funding round: ReportOpenAI backed Biossil in a US$153M funding round, valuing the Toronto-based startup at $1 billion. The round included Founders Fund, Quiet Capital, and the Abu Dhabi Investment Council. Biossil uses large language models to find drug candidates from failed clinical trials.MarketScreenerSummit Therapeutics Inc. Signs Agreement to Sell Ridinilazole to Biossil, IncSummit Therapeutics Inc. has signed an agreement to sell its drug candidate ridinilazole to Biossil, Inc. The transaction involves the transfer of rights for the company's lead development candidate, marking a strategic shift in Summit's portfolio management. This move allows Summit to focus resources on its other pipeline assets, including ivonescimab.Seeking AlphaSummit to sell antibiotic for up to $105M (SMMT:NASDAQ)Summit Therapeutics has agreed to sell its Phase 3 antibiotic asset ridinilazole to Canadian drug developer Biossil for up to $105 million, including $500,000 upfront and up to $104.5 million in milestone payments plus royalties. The drug targets Clostridioides difficile infection and was previously tested in a Phase 3 trial that failed to demonstrate superiority over the standard treatment vancomycin. Biossil plans to continue clinical development of the asset, which has received backing from Summit CEO Robert Duggan.FinancialContent Business PageSummit Therapeutics Signs Agreement to Sell Phase III Asset Ridinilazole to Biossil, Inc.Summit Therapeutics Inc. announced the signing of an agreement to sell its Phase III antibiotic asset ridinilazole to Toronto-based Biossil, Inc., an AI-native biopharma company, allowing Summit to concentrate on its core oncology strategy. Under the terms, Summit will receive $500,000 upfront and up to $104.5 million in regulatory and commercial milestones, plus tiered royalties on net sales. Ridinilazole, previously evaluated in Summit's Phase III Ri-CoDIFy study for C. difficile infection, demonstrated numerical advantages over vancomycin including microbiome preservation and lower recurrence rates, though it did not meet the primary endpoint for superiority.FierceBiotechSummit sells failed antibiotic to OpenAI-backed startup in $105M dealSummit Therapeutics has sold its failed antibiotic candidate ridinilazole to Biossil, an OpenAI-backed biotech startup, for $500,000 upfront plus up to $104.5 million in potential milestone payments. The deal allows Summit to clear an asset that failed a Phase 3 trial in 2021 and prompted the company to pivot toward ivonescimab, while Biossil continues executing its strategy of acquiring and rescuing abandoned drug programs using AI. Biossil, which emerged from stealth in April with $70 million from investors including OpenAI and Founders Fund, has shown willingness to run new trials on failed assets, including a Phase 3 trial of senicapoc in sickle cell disease.